Merger: Yes or No, page-766

First 766 Last

Share
Profile

Follow
akgo01

4,594 Posts.

668

12/12/23

21:16

Post #: 71413652
Share

Originally posted by TeBee: ↑

This is a really good post. AKE and Livent management have no doubt made mistakes, but the remoteness of Argentina is a hard place to successfully manage scientific orientated commercial operations. They should be given some leeway here.

Martin’s team tends to be criticised very hard, yet others in the business are given a relatively free pass. It doesn’t make a lot of sense to me, so I now believe that people often confuse good speakers in interviews, Q&A, and presentations with good management. They are not the same.

The reality is that all management teams in lithium have made very serious mistakes. PLS is again a prime example. They have the most articulate and best speakers by a country mile. It is very difficult to argue that they don’t have the best management team in the lithium business, yet, I feel strongly that no reasonable person can deny that cancelling BMX auctions has not been hugely damaging to retail share holders. The decision not to publish auction results in near real time took away the only real independent price transparency mechanism that existed for retail holders. Ending the auctions didn’t matter one iota to the big boys, they clearly had more reliable data, but the data they generated were hugely important for retail holders. Many retail would have sold at higher valuations had it been kept going. Martin’s team has done nothing as remotely destructive to retail holders wealth as that one decision, yet they get hammered.

Expand

"Martin’s team has done nothing as remotely destructive to retail holders wealth as that one decision, yet they get hammered."

They are on the way to destroy retail holders' wealth by endorsing this cheap reverse takeover, and making us to bear all the heavy risks while they are going to leave with a big payout

AKE Price at posting: $9.13 Sentiment: None Disclosure: Held
6 Upvote

0 Great analysis

Reply

Top Stories

CHM

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

NYR

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

NEU

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

There are more pages in this discussion • 300 more messages in this thread...

First 766 Last

Add AKE (ASX) to my watchlist

Merger: Yes or No, page-766

Top Stories

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Featured News